Rhumbline Advisers Zentalis Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 86,713 shares of ZNTL stock, worth $260,139. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,713

Previous 94,213 7.96%

Holding current value

$260,139

Previous $385,000 17.4%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$2.9 - $4.57 $21,750 - $34,275	-7,500 Reduced 7.96%	86,713 $318,000
Q2 2024 Aug 01, 2024	BUY	$4.09 - $16.13 $46,834 - $184,704	11,451 Added 13.84%	94,213 $385,000
Q1 2024 May 09, 2024	BUY	$10.83 - $16.49 $21,248 - $32,353	1,962 Added 2.43%	82,762 $1.3 Million
Q4 2023 Feb 08, 2024	SELL	$9.84 - $20.13 $688 - $1,409	-70 Reduced 0.09%	80,800 $1.22 Million
Q3 2023 Nov 09, 2023	BUY	$19.63 - $28.29 $276,194 - $398,040	14,070 Added 21.06%	80,870 $1.62 Million
Q2 2023 Aug 08, 2023	BUY	$17.41 - $30.05 $36,439 - $62,894	2,093 Added 3.23%	66,800 $1.88 Million
Q1 2023 May 11, 2023	BUY	$16.14 - $24.94 $108,622 - $167,846	6,730 Added 11.61%	64,707 $1.11 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $56,378 - $79,872	3,120 Added 5.69%	57,977 $1.17 Million
Q3 2022 Nov 10, 2022	BUY	$20.23 - $31.73 $185,569 - $291,059	9,173 Added 20.08%	54,857 $1.19 Million
Q2 2022 Aug 11, 2022	BUY	$17.91 - $52.25 $138,999 - $405,512	7,761 Added 20.47%	45,684 $1.28 Million
Q1 2022 May 12, 2022	BUY	$41.58 - $80.89 $102,910 - $200,202	2,475 Added 6.98%	37,923 $1.75 Million
Q4 2021 Feb 10, 2022	BUY	$66.92 - $84.79 $52,331 - $66,305	782 Added 2.26%	35,448 $2.98 Million
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $130,000 - $204,036	2,776 Added 8.7%	34,666 $2.31 Million
Q2 2021 Aug 05, 2021	BUY	$37.41 - $62.25 $47,922 - $79,742	1,281 Added 4.19%	31,890 $1.7 Million
Q1 2021 May 06, 2021	SELL	$35.69 - $52.72 $65,955 - $97,426	-1,848 Reduced 5.69%	30,609 $1.33 Million
Q4 2020 Feb 10, 2021	BUY	$31.71 - $57.97 $645,203 - $1.18 Million	20,347 Added 168.02%	32,457 $1.69 Million
Q3 2020 Nov 12, 2020	SELL	$27.03 - $47.97 $27,867 - $49,457	-1,031 Reduced 7.85%	12,110 $396,000
Q2 2020 Aug 13, 2020	BUY	$23.2 - $54.8 $304,871 - $720,126	13,141 New	13,141 $631,000

Others Institutions Holding ZNTL

# of Institutions

142

Shares Held

67.9M

Call Options Held

48.5K

Put Options Held

89.6K

View Full List

About Zentalis Pharmaceuticals, Inc.

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

More about ZNTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Zentalis Pharmaceuticals, Inc. Transaction History